Allogene Therapeutics

<!-- Name:DistributionId Value:8812455 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8808845 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8788429 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8741131 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic…

Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in…

ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501AProtocol Supported by…

U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming WeeksExpected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover…

RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American…

Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing ActivityPhase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for…